Natera (NTRA) 8th Annual Wolfe Research Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
8th Annual Wolfe Research Healthcare Conference summary
10 Nov, 2026Leadership transition
Solomon, an early hire in 2011, led functions across women’s health, product development and clinical genomics; he helped create Prospera and was Signatera’s original general manager.
CFO said the immediate CEO handoff avoids unclear decision authority during 2027 budget-setting; Steve remains available through a consulting agreement and will advise the leadership team.
Commercial leadership, operating cadence, territory sizing and performance measures are expected to remain consistent; existing women’s health and oncology teams remain in place.
Revenue target and Signatera economics
A $6B revenue target for 2029 was presented as an achievable goal with good execution; 2026 revenue is expected to exceed $3B, with revenue intended to double by 2029.
Signatera ASP was $1,290; a $1,450 ASP by 2029 could be supported by Medicare and MolDx coverage decisions, improved Medicare Advantage reimbursement and commercial biomarker-state reimbursement.
Eleven tumor-type dossiers have been submitted to MolDx, including liver cancer, with roughly 10 submissions remaining; further prospective outcomes data may support additional NCCN and guideline coverage by 2029.
A Signatera volume waterfall incorporates repeat tests, new patient additions and patient retention; a reasonable scenario at $1,450 ASP could put total revenue above $6B in 2029.
ASP and volume growth need not be linear; repeat testing tends to make volume progression more linear, while ASP may include step-ups or flatter periods.
Signatera market and competition
The US cancer-incidence-based model implies ~20M annual tests: ~2M diagnoses yearly multiplied by ~10 tests per patient over a typical five-year cancer journey.
Applying conservative stage-based haircuts and a long-term $2,000 ASP, supported by broader coverage and lower contracted rates, yields an estimated $20B-$40B Signatera TAM.
CFO described a potential path to 90%+ physician penetration, contingent on improving the product and continuing ambitious prospective outcomes trials.
Competitive response centers on ongoing product improvements and evidence investment; ultra-sensitive Signatera is intended to supersede the exome-based version over time, alongside a tumor-naive MRD test for selected patients.
Five-year outcomes data are available; continued investment aims to extend the evidence lead, with 10-year data expected in five years if current progress continues.
Latest events from Natera
- A $6B 2029 target builds on Signatera growth, with screening and Japan extending the runway.NTRA
UBS Global Healthcare Conference - Revenue grew 34% as volumes climbed, lifting FY2026 guidance and supporting a $6B 2029 target.NTRA
Q3 2026 - Record growth, expanding global reach, and innovation drive strong financial and operational results.NTRA
2026 Global Healthcare Conference - Record MRD growth, expanding biopharma ties, and innovation set the stage for sustained expansion.NTRA
Morgan Stanley 24th Annual Global Healthcare Conference - Record Q2 growth, product innovation, and global expansion drive strong outlook.NTRA
Canaccord Genuity's 46th Annual Growth Conference - Revenue up 38% to $753M, record test volumes, improved margins, and raised guidance.NTRA
Q2 2026 - Record growth, innovation, and AI-driven strategies are accelerating adoption and market expansion.NTRA
Morgan Stanley 23rd Annual Global Healthcare Conference - Q1 2025 revenue up 37% to $502M, record oncology growth, margin at 63.1%, net loss steady.NTRA
Q1 2025 - Record growth, innovation, and clinical momentum set the stage for major milestones in 2025.NTRA
43rd Annual J.P. Morgan Healthcare Conference 2025